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ABSTRACT

The liver is tasked with managing the concentration of various metabolites in the blood,
and of particular importance is the uptake of free fatty-acid (FFA), as elevated concentrations of
FFA are toxic to cells. FFAs are transported across the cell membrane by CD36 and distributed
by LFABP to the endoplasmic reticulum (ER), where they are esterified to glycerol, yielding
more chemically inert triglyceride (TAG), which is essential to the process of VLDL assembly.
VLDL secretion distributes energy rich TAG to peripheral tissues, and its dysfunction leads to
hepatic steatosis, which may progress into hepatocellular carcinoma. The present study examined
the role of cathepsin B (CatB) in regulating very-low density lipoprotein (VLDL) secretion
through liver fatty-acid binding protein (LFABP) cleavage as well as CD36 expression in
response to 0.5 mM oleic acid:BSA treatment, which has been reported to redistribute CatB from
the lysosome to the cytosol, where the majority of cellular LFABP is localized. Genetic knockdown of CatB in McA-RH7777 cells resulted in increased VLDL secretion as measured by 3H
TAG DPM counting and immunoblot for ApoB in cell culture media, due to increased
expression of LFABP and CD36 and increased FFA uptake. Knock-down of CatB also resulted
in decreased cellular TAG as measured by 3H DPM counting due to increased VLDL secretion.
CatB over-expression in McA-RH7777 cells resulted in decreased FFA uptake leading to
decreased VLDL secretion, which was due to increased cleavage of LFABP. Co-localization of
LFABP and CatB was observed exclusively under conditions of 0.5 mM oleic acid:BSA
treatment. Based on these results, we can conclude that CatB plays a distinct physiological role
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in the turnover of LFABP and CD36 protein, which leads to suppressed uptake of FFA, and thus,
reduced TAG synthesis and VLDL secretion.

iv

ACKNOWLEDGMENTS
The Burnett School of Biomedical Sciences has helped me grow as a person and scientist
over the past seven years by continually pushing me to learn and pass on my knowledge to
others. It has been long, tiring journey, and because of the hard work required of me and the
support I have been offered, I am living my dreams.

I would like to specifically thank Dr. Shadab Siddiqi for taking the time to be my mentor
for the past three plus years, and for assembling and running a fantastic lab that has helped me
accomplish so much.

Kristen,
Thank you for putting up with me and for sticking with me through the worst of it.

v

TABLE OF CONTENTS
TABLE OF CONTENTS ................................................................................................... vi
LIST OF FIGURES ......................................................................................................... viii
ACRONYMS ..................................................................................................................... ix
CHAPTER ONE: INTRODUCTION ................................................................................. 1
CHAPTER TWO: LITERATURE REVIEW ..................................................................... 4
VLDL Secretion and Atherosclerosis ............................................................................. 4
Cathepsin B ..................................................................................................................... 5
LFABP ............................................................................................................................ 6
CD36 ............................................................................................................................... 7
Hepatocellular Carcinoma .............................................................................................. 8
CHAPTER THREE: MATERIALS AND METHODS ................................................... 10
Reagents ........................................................................................................................ 10
Antibodies ..................................................................................................................... 10
Cell culture .................................................................................................................... 10
Immunoblotting............................................................................................................. 11
2D-DIGE ....................................................................................................................... 11
Pulse-labeling ................................................................................................................ 11

vi

Triglyceride Extraction ................................................................................................. 12
SiRNA Trasnfection...................................................................................................... 12
Plasmid Transfection .................................................................................................... 13
Statistical analysis ......................................................................................................... 13
CHAPTER FOUR: RESULTS ......................................................................................... 14
Results ........................................................................................................................... 14
Figures........................................................................................................................... 20
CHAPTER FIVE: DISCUSSION ..................................................................................... 32
REFERENCES ................................................................................................................. 40

vii

LIST OF FIGURES

Figure 1 - 2D-DIGE of Ames Dwarf Whole Cell Lysates ................................................. 20
Figure 2 - Western Blot Analysis of Ames Dwarf Whole Cell Lysates ............................. 21
Figure 3 - Cathepsin B Knock-Down Increases LFABP and CD36 Expression .............. 22
Figure 4 - Cathepsin B Knock-Down Increases VLDL Secretion .................................... 23
Figure 5 - Cathepsin B Over-Expression Decreases VLDL Secretion and Oleic Acid
Uptake ........................................................................................................................................... 25
Figure 6 - Cathepsin B Co-Localizes with LFABP after Oleic Acid Treatment ............... 27
Figure 7 - Schematic of Proposed Mechanism ................................................................ 30

viii

ACRONYMS

Apolipoprotein B (ApoB100)
Bovine Serum Albumin (BSA)
Cathepsin B (CatB)
Endoplasmic reticulum associated (ER)
Free Fatty-Acid (FFA)
Hepatocellular Carcinoma (HCC)
Liver Fatty-Acid Binding Protein (LFABP)
Low Density Lipoproteins (LDL)
Microsomal Triglyceride Transfer Protein (MTP)
Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic Steatohepatitis (NASH)
Tumor Necrosis Factor Alpha (TNFα)
Triglyceride (TAG)
Two Dimensional Difference in Gel Electrophoresis (2D-DIGE)
Very Low-Density lipoproteins (VLDL)
VLDL Transport Vesicle (VTV)
ix

Wild-Type (WT)
Peroxisome Proliferation Factor Alpha (PPARα)

x

CHAPTER ONE: INTRODUCTION

Hepatic control of lipid metabolism underlies many aspects of bodily homeostasis, and
disruptions to this process often underlie critical illness. The liver is charged with managing the
influx of free fatty-acid (FFA) from lipolysis in peripheral tissues, the uptake of chylomicron
remnants, and directly via the portal vein (1). De novo synthesis of FFA also contributes to total
hepatic lipid load. Due to their amphipathic nature, elevated concentrations of FFA disrupt
membranes which are essential to cellular function. In order to circumvent this problem,
hepatocytes employ several mechanisms, which are essential to their ability to tolerate elevated
FFA flux, and to their role in maintaining homeostasis of the whole organism.
The robust synthesis of fatty-acid binding proteins, specifically liver fatty-acid binding
protein (LFABP), which constitutes between 2-5% of hepatic cytosolic protein, serves to shield
the cytosol from the effects of elevated unesterified FFA by binding to them upon membrane
translocation (2). LFABP, as well as other members of the FABP family, mediate the
intracellular transport of FFA for synthesis of more complex lipid components by hepatocytes,
such as phospholipids and cholesterol esters, Co-enzyme A variants, and triglyceride (TAG).
These end products are essential to cellular membrane synthesis, FFA oxidation and bulk energy
storage/distribution, respectively. The synthesis of triglyceride (TAG) occurs by sequential
esterification of FFA to glycerol, forming an energy rich, highly hydrophobic, yet mostly
chemically inert end product. TAG requires little water to store in the cell as well, making this an
ideal energy storage molecule.
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Defective TAG metabolism by the liver is an important aspect of many diseases, such as
diabetes, obesity and metabolic syndrome (1), and as such, is the primary focus of the present
study. Within the liver, there are two major sites of TAG storage. Endoplasmic reticulum
associated (ER) associated TAG, and cytosolic lipid droplets. ER associated TAG is destined for
the synthesis of very low-density lipoproteins (VLDL), which will be discussed in detail later. Of
note is the fact that LFABP preferentially delivers its FFA cargo to the ER for TAG synthesis
(3). Cytosolic lipid droplets serve as a short term TAG storage pool for the liver, and are
produced by through sequential fusion with nascent VLDL.
VLDL secretion is responsible for the distribution of energy rich lipids to peripheral
tissues by the liver. Dysfunction of this process as a result of inflammation and overabundance of
lipid influx mediates the development of steatosis (4,5). This presents clinically as non-alcoholic
fatty liver disease (NAFLD), which may progress into nonalcoholic steatohepatitis (NASH),
which is a form of chronic and untreatable liver failure. In some patients, NASH then progresses
into hepatic fibrosis, then cirrhosis, finally culminating in hepatocellular carcinoma (HCC),
which is the second leading cause of cancer related deaths worldwide (6). Indeed, the balance
between VLDL secretion and LFABP mediated uptake of FFA is essential to preventing the
progression from NASH to hepatic fibrosis (3).
On the other side of the spectrum, hypersecretion of VLDL is the main underlying cause
of atherosclerosis, which is the number one underlying cause of death in the world (7). VLDL is
metabolized into low density lipoproteins (LDL) by lipoprotein lipase family enzymes, which
then become prone to oxidation. These oxidized LDL particles are taken up by artery dwelling
macrophages, which drives the growth of foam cells that expand and block off the artery (8).
2

This highlights the importance of understanding factors that regulate VLDL secretion and FFA
trafficking at the level of the hepatocyte.
Due to a naturally occurring mutation in the prop-1 gene, the Ames dwarf mouse model
lack an anterior pituitary gland and growth hormone production as a result (9). Growth hormone
deficiency in these mice lead to reduced serum TAG levels as well as improved insulin
sensitivity (10). Previous work in our lab characterized the differential expression of proteins in
Ames dwarf mice compared to wild-type (WT) litter mates using two dimensional difference in
gel electrophoresis (2D-DIGE), which showed increased expression of the cysteine protease
cathepsin B in the Ames model Figure 1.
Previous studies have shown that cathepsin B knock-out mice are resistant to diet induced
hepatic steatosis (11). Elevated levels of cystatin C, which is an endogenously synthesized
inhibitor of cathepsin B, have been identified as a risk factor for cardiovascular disease in twin
studies (12). Cathepsin B recognizes cleaves at the cognate amino acid sequence VKM in vitro
(13), which was cross referenced with our lab’s previously published proteome of the VLDL
transport vesicle (VTV) (14), which mediates the rate limiting transport of nascent VLDL
between the ER and Golgi within the hepatocyte (15). These points, coupled with our
preliminary data in Ames dwarf mice, led us to hypothesize that cathepsin B may play an as of
yet described role in regulating FFA uptake and thus VLDL secretion by cleaving LFABP.
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CHAPTER TWO: LITERATURE REVIEW

VLDL Secretion and Atherosclerosis

The process of VLDL assembly begins with the translation of the apolipoprotein B
(ApoB100) protein, which is simultaneously translocated through the ER membrane, into the ER
lumen (1). In the ER lumen TAG is added to the apoB protein as a necessary part of the folding
process by microsomal triglyceride transfer protein (MTP). In the absence of sufficient TAG to
facilitate proper folding of the apoB molecule, the nascent lipid poor VLDL particle is degraded.
This process is in fact the primary means of regulating VLDL secretion, as ApoB mRNA, which
is expressed at a steady level in hepatocytes (16).
After additional addition of lipid, which has been observed with or without MTP, the
nascent VLDL particle is selected for packaging into VTVs through interaction with the adaptor
protein CideB (17). A specialized transport system is required for packaging of nascent VLDL
particles, as canonical COPII vesicles cannot accommodate their large size (18). The trafficking
between the ER membrane and the cis-Golgi lumen is the rate limiting step in the secretion of
VLDL, which highlights the importance of understanding factors that regulate this process (15).
Fusion of the VTV specifically with the cis-Golgi membrane occurs through interaction of the vSNARE sec22b with the cognate t-SNAREs on the cis-Golgi membrane syntaxin 5, rBet1, and
GOS28 (19).
After delivery to the cis-Golgi, several important modification take place, which are
required for maturation of the VLDL particle. Phosphorylation of the ApoB protein leads to
4

conformation changes that lead to increased accommodation of TAG (1). Further glycosylations
take place, which increase the solubility of the TAG rich VLDL particle in the aqueous
environment of the blood. The VLDL particle also acquires ApoA1 in the Golgi lumen, which is
not present in the ER (20). After these essential modification, the mature VLDL particle is
packaged into post-Golgi VLDL transport vesicles (PG-VTV), which can accommodate up to
three particles for secretion into the blood. Interestingly, PG-VTVs are more similar in size to
pre-chylomicron transport vesicles, which mediate the ER to Golgi trafficking of chylomicrons
in enterocytes, and can be produced from LFABP (21). This suggests that LFABP may play an
as of yet described role in VLDL trafficking, but further experimentation is required to
substantiate this.

Cathepsin B

CatB was initially characterized as a lysosomal protease, with high activity in the acidic
milieu of this environment, where it functions primarily in protein turnover (22). It was later
shown that microsomal factions of CatB can be activated by the aspartic protease cathepsin D in
vitro at near neutral pH (23). However, it was later discovered that CatB is capable of selfcleavage, and that this readily occurs in a unimolecular process at a pH of 4.5 (24). This shows
that activation of CatB is achievable in multiple environments, through different paradigms.
CatB is translated as a pro-enzyme of approximately 39 kDa, and a 6 kDa N-terminal
fragment is removed, which occurs under both paradigms. Further proteolysis and glycosylation
of the enzyme results in formation of a 29 kDa signle chain variant, which is secreted and
5

activated by cathepsin D extracellularly. The lysosomal pool of cathepsin B is auto-processed
into the two chain, active variant, which is identified at 25 kDa (24).
More recently, is has been shown that this enzyme is able to spill into the cytosol from
the lysosome upon stimulation with TNFα or 0.5mM oleic acid (25), which occurs in a Bax
dependent manner (26). Because of this, the 25 kDa isoform, which corresponds to the two-chain
active variant of the enzyme, will be the primary focus of this study. The cytosol has an
approximately neutral pH, and under these conditions, CatB retains about 20% activity (24).
CatB mice are also resistant to TNFα mediated hepatocyte apoptosis in vivo, which
implicates CatB in the pathogenesis of liver failure (11). Additionally, CatB knock-out mice are
resistant to diet induced hepatic steatosis, which implicates a role for this enzyme in VLDL
secretion, as steatosis arises from an imbalance of TAG synthesis and secretion (5,25). Hepatic
steatosis is emerging as an underlying cause of HCC, and it has also been observed that CatB
over-expression predicts poor prognosis in HCC patients (27).

LFABP

The FABP family consists of twelve members, each with a unique expression profile and
selectivity for binding small hydrophobic ligands (28). Of the twelve, LFABP is most robustly
expressed in the liver, where is traffics FFA to the ER membrane for the synthesis of energy rich
TAG, which is necessary for the secretion of VLDL. Intestinal fatty-acid binding protein
(IFABP) is also robustly expressed in the liver, and while the two proteins have notable sequence
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homology (>90%)(2) as well as function, several distinct differences exist. This is most notable
in the stoichiometry of FFA binding, and potential sub-cellular localization. LFABP is in fact the
only member of the FABP family that binds two FFAs (as opposed to one), and has been
observed to localize to the nucleus, where it delivers ligands for activation of peroxisome
proliferation factor alpha (PPARα), which is also responsible for coordinating the synthesis of
LFABP, as well as many other genes related to lipid metabolism (29). Additionally, there are
noteworthy differences in fatty acid affinity between the two. IFABP has higher affinity for
longer chain saturated fatty acids, while LFABP has higher affinity for monounsaturated fatty
acids, such as oleic acid (2,28).
LFABP has been implicated in the pathogenesis of hepatic fibrosis by studies using
MTP/LFABP double knock-out mice (3). As mentioned previously, dysfunctional VLDL
secretion is associated with hepatic steatosis, which precedes hepatic fibrosis, which can develop
into HCC. This study illustrates that LFABP mediated uptake and delivery of FFA to the ER for
TAG synthesis leads to ER stress when VLDL secretion is impaired, and that this drives the
pathophysiology of hepatic fibrosis.
CD36

CD36 is transmembrane protein expressed by many different cell types, which mediates
the uptake of lipids and lipoproteins. Genetic knock-down of CD 36 has been shown to reduce
VLDL secretion, and exacerbate hepatic steatosis in leptin deficient mice (30). Furthermore,
hepatocyte specific disruption of CD36 has been shown to attenuate fatty liver (31). Hepatocyte
derived circulating soluble CD36 is also associated with increased fatty liver disease in patient
7

populations (32). Together, these studies highlight the important role of CD 36 in FFA uptake
and the development of steatosis
Of particular interest to the present study is the role of GH in regulating hepatic CD36
activity. Previous studies have shown that hepatocyte specific loss of GH signaling results in
drastic upregulation of hepatic CD36 and hepatic steatosis (33). Cross-breading with GH
deficient mice prevented the fatty liver phenotype due to reduced peripheral lipolysis, which is
upregulated by growth hormone. A similar phenotype is observed in the Ames dwarf mice used
in the present study, which also lack growth hormone.
Hepatocellular Carcinoma

HCC is the second leading cause of cancer related deaths worldwide, and remains one of
the most aggressive and difficult to treat forms of liver cancer (6). While many different
underlying causes of HCC exist, with hepatitis B/C being the most common, the proportion of
patients with no etiology outside of NASH is rapidly growing, and patients who fall into this
category are typically diagnosed at a later stage, and have a poorer prognosis than those others
(34).
Recent advance in the understanding of NASH induced HCC have pointed to adipose
tissue dysfunction and chronic, diet induced inflammation as underlying causes of
hepatocarcinogenesis. Adipose specific deletion of prohibitin induced obesity, which resulted in
chronic low-grade inflammation accompanied by insulin resistance developed into hepatic
steatosis and finally HCC (35). This effect and the observed alteration in adipokines was male
specific, which is interesting, as HCC is more prevalent in males on an epidemiological level.
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Tumor tissue from these mice showed increased ERK1 phosphorylation, suggesting that
increased ERK signaling may underlie HCC development. Previous reports have shown that
hepatoma cell lines which secrete an increased number of VLDL particles display increased
ERK signaling, and that this defect is corrected with MEK/ERK inhibition (36). This suggests
involvement of a common signaling pathway in elevated VLDL secretion, which directly
contributes to obesity, and HCC development in an obese, insulin resistant mouse model.
Other studies have shown that obesity induced changes in gut microbiota can influence
HCC development, specifically through increased gram positive cell wall components leading to
TLR4 mediated inflammation and subsequent increased prostaglandin synthesis and suppressed
tumor surveillance (37). Increased preponderance of gram positive microbiota is consistent with
previously reported changes in microbiota due to obesity and high fat diet (38).
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CHAPTER THREE: MATERIALS AND METHODS

Reagents - Albumin was purchased from Sigma. Recombinant rat growth hormone was
purchased from Abcam (cat. # ab68388). Immunoblot reagents were attained from Bio-Rad.
ECL (enhanced chemiluminescence) reagents were purchased from GE Healthcare. Other
reagents were of analytical grade and purchased from local vendors. Ames dwarf (df/df) mice
were a gift of Dr. Michal Masternak. All animal procedures were performed in accordance with
University of Central Florida Institutional Animal Care and Use Committee (IACUC) guidelines
and in strict agreement with the IACUC approved protocol.

Antibodies - Anti-Rabbit IgG antibodies conjugated to HRP were purchased from Santa Cruz
Biotechnology. Rabbit polyclonal antibodies targeting Cathepsin B, ApoB, and LFABP were
purchased from Santa Cruz Biotechnology.

Cell culture - Rat hepatoma cells (McA-RH7777 cells) were obtained from American Type
Culture Collection (ATCC) were maintained on Dulbecco's modified Eagle's medium (Life
Technologies) supplemented with 5% fetal bovine serum (ATCC) and 1%
penicillin/streptomycin (Sigma Chemical Co.). Cell lysates were collected with radioimmune
precipitation assay buffer (Thermo Scientific, Rockford, IL) (RIPA) Lysis and Extraction Buffer
supplemented with protease inhibitor (Roche Applied Science) according to manufacturer
instructions. Additional treatments were performed as indicated in figure legends.
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Immunoblotting - Protein concentrations were determined by the Bradford assay as performed
previously (8). Samples were resolved by SDSPAGE with gel concentrations indicated in figure
legends. Proteins were then transferred to nitrocellulose membranes (Bio-Rad) and detection was
performed using ECL (GE healthcare) and autoradiography film (MIDSCI, St. Louis, MO).

2D-DIGE - Samples were prepared resolved, and analyzed according to manufacturer
instructions. Briefly, equal mass of protein was labeled with Cy3 or Cy5 fluorescent dye. The
samples were then mixed, loaded onto an 11-cm IPG strip, and subject to isoelectric focusing for
21 hours using a total of 50,500 volt-hours. After isoelectric focusing, the IPG strip was
equilibrated, loaded onto a 4-20% gradient tris HCl gel, resolved, and scanned using the
Typhoon TRIO (GE Healthcare). ExPASy protein data base was used for putative identification
of protein spots.

Pulse-labeling - 3H oleic acid (45.5 Ci/mm) was purchased from PerkinElmer Life Sciences. For
pulse labeling experiments, 0.3x10^6 cells were plated in each well of a six-well plate.
Transfections were performed simultaneous to plating as described below. For experiments
requiring RNA interference, media was discarded after 48 hours and the cells were washed twice
using fresh media without penicillin/streptomycin. Cells were incubated in 0.4mM oleic acid
containing 2μM 3H oleic acid for one hour. The pulse was then discarded, the cells washed twice
as described previously to remove residual labeled oleic acid, and given fresh 5% FBS
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containing DMEM. 200μl aliquots were taken at indicated time intervals. Radioactivity (dpm)
associated with 3H TAG was measured from 100 μl media aliquots by liquid scintillation
counting using Tri-Carb 2910TR liquid scintillation analyzer (PerkinElmer Life Sciences).
Media was changed four hours after transfection with plasmid to avoid toxicity.

Triglyceride Extraction - Protein concentrations were determined by the Bradford methods as
described previously (8). Whole cell lysates from McA-RH7777 cells were collected as escribed
previously, with any prior treatment indicated in the figure legend. 50μg of whole cell lysate
protein with 3H oleic acid labeled triglyceride was diluted to 200μl with PBS and mixed with 1.5
ml of isopropanol/n-heptane/ d.i. H20 (80/20/2; v/v), vortexed vigorously, and allowed to settle.
1 ml of n-heptane and 0.5 ml of d.i. H20 was added. The mixture was vortexed and spun until
separation of the organic layer. The organic layer was collected and mixed with 2ml of 0.5N
NaOH/EtOH/ d.i. H20 (1/5/5; v/v), vortexed, and spun until separation of the organic layer. The
organic layer (n-heptane) containing 3H oleic acid labeled triglyceride was subject to liquid
scintillation counting as described previously.

SiRNA Trasnfection - McA-RH7777 cells were transfected using Lipofectamine RNAiMax
(ThermoFisher Sceintific) according to manufacturer instructions. A final concentration of 25
mM Cathepsin B siRNA (Silencer select predesigned siRNA, Life Technologies; cat. # s134210)
as used for all knock-down experiments.
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Plasmid Transfection – pCI-Neo vector containing rat Cathepsin B gene insert (RefSeq i.d.
NM_022597.2) was purchased from Life Technologies. Transfection was carried out using
Lipofectamine 2000 according to manufacturer instructions.

Statistical analysis - Data were compared using a GraphPad Software (GraphPad Prism 5
Software for Mac OS X version) employing either a twotailed t test or a one-way analysis of
variance (ANOVA).
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CHAPTER FOUR: RESULTS

Results

Differential Protein Expression in Ames Dwarf Whole Cell Lysates – We first sought to
identify proteins that were differentially expressed in Ames dwarf mice livers that could explain
their reduced VLDL secretion and serum TAG when compared to their wild type littermates.
Differential analysis of protein expression in Ames dwarf mice livers was performed by
2DDIGE against matched samples from their wild type littermates. Cy3 dye (green) was used to
label Ames dwarf whole cell lysates and wild type samples were labeled with Cy5 dye (red). We
identified a green spot (white circle; Figure 1) at approximately 25 kDa with an isoelectric point
of 5.0 to 5.5, which was putatively identified cathepsin B by cross referencing with the ExPASy
protein data bank. Our results indicate that Ames dwarf liver Figure 1 expresses greater amounts
of cathepsin B than wild type litter mates.
We validated this observation with immunoblot analysis, which shows 227% increased
expression of cathepsin B in (df/df) whole cell lysates when compared to wild type litter mates
Figure 2 a-b. We decided to further investigate the potential role of cathepsin B in regulating
VLDL assembly due to its robust expression in the liver of Ames dwarf mice, and previous
studies indicating that cathepsin B knock-out mice are resistant to diet induced hepatic steatosis
(11). We hypothesized that the previously reported phenotype of reduced VLDL secretion may
be in part due to increased expression of cathepsin B, leading to decreased expression of VLDL
14

and FFA trafficking proteins as a result of cathepsin B cleavage. Interestingly, we observed a
56% decrease in expression of the FFA trafficking protein LFABP in (df/df) hepatocyte whole
cell lysates when compared to wild type littermates Figure 2a-b.
Previous studies have established that cathepsin B cleaves at the C-terminal aspect of the
VKM cleavage sequence in vitro (13). Our lab has previously published a comprehensive
proteomic analysis of the VTV (14), which was used to compile a list of relevant proteins
containing this sequence, which were all retrieved from the UniProt protein data bank. We were
able to identify the VKM cleavage sequence within LFABP Figure 2c, a protein which has been
implicated in trafficking fatty acids to the ER from the cell surface receptor CD36, also known as
FFA translocase (28). It is well established that ApoB translation occurs at a somewhat steady
rate, and that ApoB stability is depends upon ER TAG availability (1). Thus, we proposed a
mechanism in which cathepsin B restricts the flow of FFA to the ER for TAG synthesis by
cleavage of LFABP. This would lead to reduced VLDL secretion by limiting ER TAG
availability. This observation provides a potential mechanistic basis for the observed decrease in
VLDL secretion seen in Ames dwarf mice, as well as the increased rate of TAG esterification
and VLDL secretion induced by GH administration. These observations may also provide insight
into the role of the cathepsin B in the progress of NAFLD from simple steatosis by disrupting
normal secretion of VLDL and uptake of FFA.
Impact of Cathepsin B siRNA Treatment on FFA Trafficking Protein Expression and
VLDL Secretion – To substantiate this hypothesis, we wanted to determine if genetic knockdown of cathepsin B would lead to increased LFABP protein levels. Treatment with cathepsin B
specific siRNA delivered by lipofectamine resulted in an 80% decrease in expression of the
15

cathepsin B protein when compared to whole cell lysates from control siRNA treated cells
Figure 3a-b. Under the conditions of cathepsin B knockdown in McA-RH7777 cells, one hour of
oleic acid exposure (0.4 mM) lead to a 74% increase in levels of LFABP protein when compared
to control siRNA treated cells Figure 3a-b. The observed difference in LFABP protein levels
was not observed when cells were deprived of oleic acid stimulation (data not shown). This
provides evidence for a mechanism in which cathepsin B cleavage of cytosolic LFABP occurs in
an oleic acid dependent manner.
A pulse-labeling approach was used to determine if cathepsin B knock-down increases
VLDL secretion or not. We tested this under the conditions of treatment with 0.5 mM oleic acid
complexed to 10% BSA for 24 hours as well as treatment with 10% BSA in PBS to analyze the
impact of cathepsin B knock-down under conditions of elevated and reduced FFA availability,
respectively. Interestingly, McA-RH7777 cells treated with 0.5μM oleic acid for 24 hours and
cathepsin B specific siRNA express 70% greater amount of the cell surface FFA translocase
CD36 when compared to oleic acid pre-treated cells transfected with control siRNA Figure 3c-d.
Without oleic acid pre-treatment, cathepsin B knock-down alone resulted in a 31.5% increase in
CD36 expression relative to control siRNA Figure 3c-d. Under conditions of oleic acid pretreatment and cathepsin B knockdown, we observed at 39% increase in TAG secretion into the
media after one hour when compared to control siRNA Figure 4a as measured by [3H] DPM
counting. The observed increase in [3H] TAG was maintained above 20% through the 2, 4, and 6
hour time points Figure 4a. Without 24-hour oleic acid pre-treatment, we observed a 15%
increase in TAG secretion after 1 hour relative to the control siRNA Figure 4a, which remained
above 10% through the 2, 4, 6 hour time points, but did not meet statistical significance.
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We then sought to determine if the increase in TAG secretion observed under conditions of
cathepsin B knock-down were due to an increased number of VLDL particles secreted. The
VLDL particle contains only one ApoB molecule, while TAG content may vary slightly. As
such, the number of VLDL particles secreted will be proportional to ApoB secretion. Media time
points analyzed in the pulse-labeling experiment were subject to immunoblot, and the results
show that cathepsin B knock-down resulted in a 115% increase in secretion of ApoB into the
media relative to cells treated with control siRNA at the 1 hour time point Figure 4b, which was
consistent across the remaining time points. These results indicate that cathepsin B knock-down
leads to an increased number of VLDL secreted from McA-RH7777 cells, which is in line with
our proposed mechanism. With this established, we sought to determine to what extent cathepsin
B knockdown would impact cellular TAG content in McA-RH7777 cells after the 24-hour chase
period. An equal mass of whole cell lysate (50μg) from knock-down and control siRNA treated
samples was subject to TAG extraction and, the final organic phase containing TAG was
analyzed by [3H] DPM counting. Cathepsin B knock-down resulted in a 32% decrease in cellular
[3H] TAG content after a 1 hour chase period Figure 4c. This result is expected, and occurs as a
result of increased VLDL TAG secretion, which was observed under these conditions Figure 4ab. These data suggest that the observed increase in VLDL secretion is a result of increased
LFABP and CD36 levels Figure 3a-d, secondary to cathepsin B knockdown. This promotes
greater FFA availability for TAG synthesis in the ER, which leads to increased stability of
nascent VLDL, resulting in increased secretion of VLDL. This process occurred in an oleic acid
dependent manner, suggesting cleavage of LFABP that requires translocation of cathepsin B
from the lysosome.
17

Over Expression of Cathepsin B Decreases VLDL Secretion and Cellular TAG – In order
to increase our confidence in the proposed mechanism, we established an over-expression
protocol using the pCI-Neo vector containing the cathepsin B gene insert. After transfection with
the plasmid containing insert, we observed a 34% increase in cathepsin B expression relative to
control cells transfect with the empty vector Figure 5a. We suspected that cells over-expressing
cathepsin B would secrete a reduced VLDL as a result of decreased FFA uptake and TAG
synthesis. We performed a similar pulse-labeling protocol as was described for siRNA treatment,
with the exception of withholding 24-hour oleic acid pretreatment. This was omitted as a result
of toxicity to the cells, which was observed when combined with plasmid transfection using
lipofectamine 2000. Secretion of TAG into the media was decreased by 24% after two hours in
cells overexpressing cathepsin B, as measured by [3H] DPM counting, and remained above a
15% decrease through the 6 and 24-hour time points Figure 5b. This result in in line with the
proposed mechanism in which LFABP cleavage by cathepsin B results in reduced TAG
availability for VLDL secretion.
With this in mind, we sought to determine the impact of cathepsin B overexpression on
cellular retention of our [3H] oleic acid. We found that over-expression of cathepsin B led to a
23% decrease cellular [3H] TAG compared to control cells expressing only the empty vector
after the 24-hour pulse-chase Figure 5c, which can be attributed to reduced uptake of the [3H]
oleic acid marker during the pulse phase. This suggests that the observed reduction on [3H] TAG
secretion seen under conditions of cathepsin B overexpression can be attributed to decreased
FFA uptake as a result of cathepsin B regulation of LFABP and CD36 protein levels.
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Thus far, we have established that knockdown of cathepsin B leads to increased LFABP and
CD36 when cells are exposed to oleic acid. We have also established that this leads to increased
VLDL secretion as measured by [3H] TAG dpm counts and VLDL-apoB100, and a decrease in
cellular [3H] TAG. Furthermore, cathepsin B over-expression leads to decreased FFA uptake and
reduced VLDL secretion as a byproduct of this mechanism. In our proposed mechanism,
cytosolic cathepsin B regulates LFABP, which in turn regulates TAG availability for VLDL
secretion. Dual labeling of McA-RH7777 cells was performed to test if LFABP co-localizes with
ApoB as well as cathepsin B or not. Co-localization of LFABP with cathepsin B was performed
with or without oleic acid pretreatment to determine what impact these conditions have on
interaction between the two proteins. In the absence of oleic acid-treatment, co-localization of
LFABP with ApoB was determined based on the presence of yellow (top right panel, Figure 6)
staining pattern in the merged LFABP/ApoB image. However, no colocalization of LFABP and
cathepsin B was observed in the absence of oleic acid treatment, (middle right panel, Figure 6),
indicating that under these conditions the two proteins are segregated from each other in McARH7777 cells. However, when cells were subjected to one hour of oleic acid treatment (0.5 mM),
a distinct co-localization of LFABP and cathepsin B was observed in a distinctive pattern, which
is consistent with localization to the Golgi apparatus (bottom right panel, Figure 6).
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Figures

Figure 1 - 2D-DIGE of Ames Dwarf Whole Cell Lysates
2D-DIGE analysis of Ames dwarf whole cell lysates. Two-dimensional differential gel
electrophoresis (2D-DIGE) analysis of hepatic proteins from Ames dwarf (df/df) and wild type
(WT) mice. Whole cell lysate (WCL) proteins (300 μg) from hepatocytes of df/df and WT mice
labeled with Cy3 and Cy5 dye, respectively. Post-labeling, equal amount of proteins from each
sample were mixed together and solubilized in 2D-gel buffer followed by isoelectric focusing
using a total of 50,500 volthours. After equilibration, proteins were separated by 4-20% SDSPAGE and the gel was scanned utilizing Typhoon TRIO (GE Healthcare). White circle indicates
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spot putatively identified as CatB. 2D-DIGE was performed by Faisal Moinuddin and used with
permission.

Figure 2 - Western Blot Analysis of Ames Dwarf Whole Cell Lysates
Cathepsin B and LFABP expression in Ames dwarf mice. A. Immunoblots of hepatocyte
whole cell lysates of Ames dwarf (df/df) and wild type (WT) mice. 40 μg protein from whole
cell lysates was resolved on a 12% SDS-PAGE gel, trans-blotted onto a nitrocellulose membrane
and probed with the indicated antibody. B. The amount of Cathepsin B (CatB), LFABP and b actin per 40 μg of fraction protein (as shown in Fig. 2A) was determined by analyzing protein
band density using NIH Image J program. The results are the mean ±SD (n =4). Bars labeled
with asterisk show p values using one-way ANOVA; *** p < 0.001. Bars labeled with ns show
non-significant p values. C. The sequence of established VTV protein components, which were
previously identified by our lab (14), were mined from UniProt protein database. The library of
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protein sequences was scanned for the VKM sequence recognized by Cathepsin B (CatB) using
Microsoft Word search function. LFABP was the only identified protein.

Figure 3 - Cathepsin B Knock-Down Increases LFABP and CD36 Expression
Knockdown of Cathepsin B by siRNA transfection increases LFABP and CD36
expression in McA-RH7777 cells. A. McA-RH7777 lysates analyzed were subject to the pulse
chase protocol as described below and in methods. 40 μg protein from whole cell lysates was
resolved on a 12% SDSPAGE gel, trans-blotted onto a nitrocellulose membrane and probed with
the indicated antibody. B. The amount of Cathepsin B (CatB), LFABP and β-actin per 40 μg of
cellular protein (as shown in Fig. 3A) was determined by analyzing protein band density using
NIH Image J program. The results are the mean ±SD (n =4). Bars labeled with asterisk show p
values using one-way ANOVA; ** p < 0.005; *** p <0.001. Bars labeled with ns show nonsignificant p values. C. Samples analyzed were representative whole cell lysates from pulse22

chase experiment with oleic acid pre-treatment. Cells were treated with oleic acid complexed to
BSA or just BSA as indicated. ImageJ was used for quantification. D. The amount of CD36 and
b -actin per 40 μg of fraction protein (as shown in Fig. 3C) was determined by analyzing
protein band density using NIH Image J program. The results are the mean ±SD (n =3). Bars
labeled with asterisk show p values using one-way ANOVA; * p < 0.05; ** p < 0.005. Bars
labeled with ns show non-significant p values.

Figure 4 - Cathepsin B Knock-Down Increases VLDL Secretion
Cathepsin B knockdown increases VLDL secretion and reduces cellular TAG in McARH7777 cells. A. 0.3X106 McA-RH7777 cells were plated in each well of two six-well plates,
and transfected using Lipofectamine RNAiMAX at a final concentration of 25nm cathepsin B
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specific siRNA (siCatB) or siRNA control (siControl). 24 hours after transfection, three wells of
each were supplemented with 0.5μM oleic acid complexed with BSA (10% final concentration)
or PBS with 10% BSA. 48 hours after transfection, each well was washed and subject to 1 hours
pulse, with 0.4 mM oleic acid:BSA complex and 2μCi 3H oleic acid in DMEM supplemented
with 5% FBS. The pulse was removed and each well was washed twice with fresh media to
remove residual label, and filled to 3ml with DMEM supplemented with 0.5% FBS. Indicated
time points were collected in 200 μl aliquots, and subject to liquid scintillation counting to
determine [3H] TAG secretion by presence of the 3H oleic acid label in media. 0-hour time point
was subtracted as background. The data are the mean ±SD (n =6). Bars labeled with asterisk
show p values using one-way ANOVA; * p < 0.01; ** p < 0.002. Bars labeled with ns show nonsignificant p values. B. 30 μl of media from cells treated with cathepsin B specific siRNA
(siCatB) or siRNA control (siControl) at indicated pulse-chase time points was resolved on a
12% SDS-PAGE gel, trans-blotted onto a nitrocellulose membrane and probed with the indicated
antibody. The amount of secreted VLDLapoB100 was determined by analyzing protein band
density using NIH Image J program. The results are the mean ±SD (n =3). Bars labeled with
asterisk show p values compared with control siRNA using one way ANOVA; ** p < 0.001. C.
50 μg of protein from McA-RH7777 whole cell lysates treated with cathepsin B specific siRNA
(siCatB) or siRNA control (siControl) was adjusted to a final volume of 200μl with PBS. The
diluted lysates were then subject to solvent extraction as described in methods, and the final
organic layer containing 3H labeled TAG was subject to liquid scintillation counting to
determine cellular retention of the 3H label incorporated into TAG. The data are the mean ±SD
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(n =3). Bars labeled with asterisk show p values compared with control siRNA using one-way
ANOVA; ** p < 0.005

Figure 5 - Cathepsin B Over-Expression Decreases VLDL Secretion and Oleic Acid Uptake
Cathepsin B over-expression decreases VLDL secretion and FFA uptake. A. McARH7777 lysates analyzed were subject to the pulse chase protocol as described below. 40 μg
protein from whole cell lysates was resolved on a 12% SDS-PAGE gel, trans-blotted onto a
nitrocellulose membrane and probed with the indicated antibody. B. 0.3X106 McA-RH7777
cells were plated in each well of two sixwell plates, and transfected using Lipofectamine 2000
with each well containing a final mass of 2.5μg of the PCI-Neo vector containing the cathepsin B
gene insert (n=3) or empty vector (n=3). 48 hours after transfection, each well was washed and
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subject to 1 hours pulse, with 0.4 mM oleic acid:BSA complex and 2μCi 3H oleic acid in DMEM
supplemented with 5% FBS. The pulse was removed and each well was washed twice with fresh
media to remove residual label, and filled to 3ml with DMEM supplemented with 0.5% FBS.
Indicated time points were collected in 200 μl aliquots, and subject to liquid scintillation
counting to determine 3H TAG secretion by presence of the [3H] oleic acid label in media. 0hour time point was subtracted as background. The data are the mean ±SD (n =3). Bars labeled
with asterisk show p values using one-way ANOVA; * p < 0.02; ** p < 0.005. Bars labeled with
ns show non-significant p values.C. 50 μg of protein from McA-RH7777 whole cell lysates
treated with PCI-Neo vector containing the cathepsin B gene insert (n=3) and empty vector (n=3)
was adjusted to a final volume of 200μl with PBS. The diluted lysates were then subject to
solvent extraction as described in methods, and the final organic layer containing [3H] labeled
TAG was subject to liquid scintillation counting to determine cellular retention of the [3H] label
incorporated into TAG. The data are the mean ±SD (n =3). Bars labeled with asterisk show p
values using one-way ANOVA; ** p < 0.002.
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Figure 6 - Cathepsin B Co-Localizes with LFABP after Oleic Acid Treatment
LFABP co-localizes with ApoB, and does not co-localize with cathepsin B. (Top panel):
McA-RH7777 cells were double labeled with LFABP (FITC, green) and apoB (Texas red),
merged image shows co-localization. Nuclei were stained with DAPI. (Middle panel): McARH7777 cells were double labeled with LFABP (FITC, green) and CatB (Texas red), merged
image shows no co-localization of proteins. Nuclei were stained with DAPI. (Bottom panel):
McA-RH7777 cells were treated for one hour with 0.5mM oleic acid complexed to BSA prior to
being double labeled with LFABP (FITC, green) and cathepsin B (CatB) (Texas red). Nuclei
were stained with DAPI. Merged image shows co-localization of LFABP and cathepsin B (CatB)
in OA-treated McA-RH7777 cells.
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Figure 7 - Schematic of Proposed Mechanism
A. Illustration of VLDL secretion under conditions of high FFA availability. CD
36 mediates translocation of FFA across the cell membrane. LFABP mediates distribution of
FFA to the ER for TAG synthesis, which stabilizes ApoB, allowing VLDL synthesis to proceed.
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B. In the absence of sufficient TAG, the ApoB protein cannot fold properly, which leads to
recruitment of Hsp70 and Hsp 90 chaperones, and subsequent ubiquitination by the E3 ubiquitin
ligase gp78. This leads to degradation of ApoB in the cytosol. C. Knock-down of CatB leads to
increased LFABP and CD36 protein levels after oleic acid treatment, which in turn provides
more FFA for TAG synthesis. This leads to increased stability of the ApoB molecule, and
increased VLDL secretion.
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CHAPTER FIVE: DISCUSSION

The liver is responsible for maintaining energy homeostasis in the body through
processes such as gluconeogenesis, fatty acid synthesis, and VLDL secretion. The precise
balancing of these processes is required for maintaining the necessary availability of each
metabolite, and a failure to effectively regulate any poses serious consequences to general health.
Hyper-secretion of VLDL, which may occur as a result of insulin resistance, is a major risk
factor for the development of atherosclerosis, highlighting the importance of developing a
detailed understanding of this process (39,40). Regulation of VLDL secretion is controlled by
TAG availability as well as hormonal milieu, and degradation of apoB at the ER level has been
long established as essential to directing this process (16). Flux of FFA to the ER is mediated by
the lipid binding and trafficking protein LFAPB, and the cell surface receptor CD36, which
mediates the translocation of FFA across the cell membrane (2). TAG synthesized from this pool
is added to the apoB molecule by MTP as it is synthesized and simultaneously transported across
the ER membrane, into the ER lumen. In the absence of sufficient TAG, this process is stalled.
This causes hsp70 and hsp90 bind to unfolded portions of the stalled apoB molecule, which is
ubiquitinated by the E3 ligase gp78 Figure 7b. This targets the core VLDL protein for
degradation by the ERAD system in the cytosol (16). This highlights the importance of
understanding processes that regulate FFA flux, which is essential to VLDL secretion, and thus
relevant to cardiovascular disease.
Once synthesized, the nascent VLDL particle must be trafficked between the ER and
Golgi and due to the size of nascent VLDL, a special packaging system is required for
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transportation (15). The VLDL transport vesicle, or VTV, is biochemically distinct from other
COPII derived vesicles that are responsible for the movement of nascent proteins between the
ER and Golgi. Electron microscopy has revealed that VTVs, which contain ApoB100, are 100120nm in diameter, while protein transport vesicles (PTV), which contain the secretory protein
albumin, are 55-70nm Figure 7a (15). This process is the rate limiting step in the secretion of
VLDL, which highlights the importance of understanding its regulation at the molecular level
(15).
After delivery to the cis-Golgi lumen, several steps are required in maturation of the
VLDL particle prior to secretion into the blood. The addition of complex carbohydrate moieties
leads to increased buoyancy of the lipid rich VLDL particle (41), while phosphorylation of
theApoB backbone leads to structural rearrangements (42). The addition of further triglyceride
within this compartment is still a matter of debate, with groups showing conflicting evidence for
each case (43,44). It has also been established that VLDL acquires ApoA1 in the Golgi lumen,
which is not present on the nascent VLDL during transport in the VTV, though the explicit role
for this modification has not been established (20). Secretion of mature VLDL occurs by the
formation of distinct post-Golgi VLDL transport vesicles (PG-VTV), which are able to fuse with
the plasma membrane (20). PGVTVs are 300-350nm in diameter and able to accommodate up to
three mature VLDL particles (20).
The present study establishes that Ames dwarf mouse liver has 227% increased
expression of the cysteine protease cathepsin B and 56% decreased expression of the FFA
trafficking protein LFABP, which contributes to their observed reduction in VLDL secretion and
serum TAG relative to wild type littermates (10). We have also shown that LFABP co-localizes
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with apoB, suggesting that LFABP plays some as of yet described role in the assembly and
trafficking of VLDL beyond delivery of FFA. Based on size similarity of PCTVs and PG-VTVs,
this may be related to post-Golgi trafficking of VLDL, but further study is required to
substantiate this hypothesis.
It has been observed that cathepsin B is able to translocate to the cytosol upon stimulation
with oleic acid or TNFα (11,12). Analysis of the VTV proteome revealed that LFABP, one of the
most abundant cytosolic proteins in hepatocytes, contains the cognate VKM cleavage sequence
which is cleaved by cathepsin B in vitro (13). The results of the present study show that
knockdown of cathepsin B with siRNA leads to reduced degradation of LFABP, resulting a 74%
increase in LFABP protein expression when exposed to at least 0.4mM oleic acid for one hour.
One hour of oleic acid exposure was also sufficient to redistribute the staining pattern of
cathepsin B, and induce co-localization with LFABP, which was not observed without oleic acid
treatment in the present study Figure 6Figure 1. Regulation of LFABP levels by protease
cleavage have been suggested previously (28,29), with reports showing increased stability of
LFABP bound to oleic acid. Taken with the present data, this suggests that cathepsin B mediates
turnover of LFABP after delivery of FFA cargo. Future studies are planned to confirm the
requirement for the VKM consensus sequence by over-expression of an LFABP variant
containing point mutations in the VKM sequence.
Elevation of cytosolic cathepsin B can be driven by conditions of elevated serum FFA or
chronic TNFα production, which are both observed in insulin resistance, and may contribute the
progress of hepatic steatosis through the novel mechanism described in this study (45). Thus, the
suppression of elevated FFA concentration, or inhibition of cathepsin B activity, could serve to
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slow down the progression of hepatic steatosis through restoring functional VLDL secretion and
FFA uptake by the liver. A 39% increase in [3H] TAG secretion after one hour by McA-RH7777
cells supplemented with 0.5mM oleic acid complexed to BSA for 24 hours was observed as a
result of cathepsin B knock-down. This is logically supported by a previous twin study showing
increased atherosclerotic cardiovascular disease in association with increased cystatin C levels,
which is an endogenously produced inhibitor of cathepsin B (12). This suggests cathepsin B
inhibition may be effective in restoring VLDL secretion and slowing the progress of hepatic
steatosis, but this may result in unwanted increases in VLDL secretion and risk for
atherosclerotic cardiovascular disease, which must also be managed carefully. Increased VLDL
secretion observed in the present study was accompanied by a 70% increase in expression of
CD36, suggesting increased FFA uptake as a result of cathepsin B knock-down. Without oleic
acid pre-treatment, [3H] TAG secretion was increased by 15% after one hour, and CD36
expression increased by 31.5% as a result of cathepsin B knock-down. These results suggest that
cathepsin B regulates cellular CD36 and LFABP protein levels, and that this mechanism restricts
the flow of FFA via LFABP and CD36 for TAG synthesis and VLDL secretion. This mechanism
may help to explain why cathepsin B knock-out mice are resistant to diet induced hepatic
steatosis, as cathepsin B knockdown resulted in a 32% decrease in cellular TAG as measured by
retention of the [3H] oleic acid as TAG. This observation was attributed to the increase in VLDL
(apoB) secretion Figure 7c.
Cathepsin B over-expression resulted in a 24% decrease in [3H] TAG secretion after 2
hours, as well as a 23% decrease in retention of our [3H] oleic acid as TAG after 24 hours of
secretion. This is in agreement with decreased FFA uptake during the initial pulse period, which
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can be attributed to regulation of LFABP and CD36 expression by cathepsin B. Transfection
with the CatB containing pCI vector resulted in a consistent 34% increase in expression of the 25
kDa CatB isoform as determined by ImageJ analysis Figure 5a. This band represents the mature,
two-chain, active isoform of CatB, which is why it is of interest (24). Whole cell lysates from
Mac-RH7777 cells were analyzed by immunoblot analysis to determine whether or not CatB
over-expression resulted in decreased LFABP expression. A 38% decrease in LFABP expression
was observed in Mac-RH7777 cells expressing the CatB gene insert when compared to control
Figure 5a. A minimum of 0.4 mM oleic acid:BSA incubation for 1 hour was required for the
observed change in LFABP expression to be observed. The minimum requirement for oleic acid
incubation is consistent with the proposed mechanism of lysosomal CatB redistribution that has
been previously reported (26). Longer oleic acid incubation periods (24 hours) were required for
the observed cytosolic distribution of the GFP-CatB fusion protein that was used in the
aforementioned study. This was limited in the over-expression experiments due to toxicity when
combined with long term oleic acid treatment.
CD36 has also been implicated in providing FFA for the synthesis of VLDL associated
TAG (30). In the present study, genetic knock-down of CatB and oleic acid:BSA incubation
resulted increased CD36 expression in an additive manner. Previous studies have shown that GH
directly suppresses the expression of CD36 in a PPAR gamma dependent manner (33). This
suggests that Ames dwarf mice should express more CD 36 as a result of GH deficiency, making
it difficult to extrapolate the impact CatB could have in directly regulating CD36 expression in
this model. However, increased expression of CD 36 has been observed to increased VLDL
secretion, which is the opposite of what has been observed in Ames dwarf mice (10). This
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suggests that some other mechanism must exist that is preventing elevated secretion of TAG by
Ames dwarf mice. The results of the present study suggest that increased LFABP turn-over due
to elevated CatB expression may restrict the flow of FFA to the ER for TAG synthesis in Ames
dwarf mice, thus explaining their observed phenotype of reduced VLDL secretion.
This explanation is consistent with the observed phenotype of LFABP knock-out mice,
which much like Ames dwarf mice, are lean, resistant to diet induced obesity and hepatic
steatosis, and produce fewer VLDL particles (46,47). This can be attributed to the role of LFABP
in uptake of FFA, and delivery to the ER specifically for synthesis of TAG, which will be
associated with VLDL. Dysfunction of this process is essential to the pathogenesis of hepatic
fibrosis, as MTP knock-out mice, which have impaired secretion of VLDL, are resistant to diet
induced hepatic steatosis when cross-bread with LFABP knock-out mice (double knock-out) (3).
This highlights the importance in understanding the regulation of LFABP protein levels in
hepatocytes, as this implicates LFABP in the progression from hepatic steatosis to hepatic
fibrosis under conditions of impaired VLDL secretion.
We then sought to determine the conditions in which LFABP is co-localized with ApoB
and CatB. Mac-RH7777 cells were double labeled, with LFABP green (FITC) and ApoB red
(Texas Red), with areas of yellow indicating co-localization. LFABP was observed to interact
with ApoB in a diffuse, and completely over-lapping pattern Figure 6 (top, far right panel),
which occurred without oleic acid treatment. No difference in co-localization of ApoB and
LFABP was observed as a result of oleic acid treatment (data not shown).
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Co-localization of LFABP and CatB was only observed under conditions of one hour
oleic acid:BSA incubation. This is consistent with a mechanism of oleic acid induced, Bax
mediated lysosomal permiabilization, which has previously been shown to redistribute CatB to
hepatic cytosol (26). The results of the present study suggest that one hour of 0.4 mM oleic acid
incubation may redistribute CatB to the cytosolic aspect of the Golig apparatus, but further colocalization with Golgi specific marker proteins is required to confirm this as the location of
CatB:LFABP interaction induced by oleic acid. As mentioned previously, 24 hours of oleic acid
exposure was required to induce the cytosolic redistribution of CatB (26). We have planned
future experiments to determine the co-localization of CatB and LFABP under these conditions.
We expect to see a more diffuse pattern of CatB staining, with a greater degree of co-localization
with LFABP.
A role for cathepsin B in regulating gene expression may exist through LFABP cleavage,
as LFABP has been shown to deliver hydrophobic ligands to the nucleus and regulate PPARα
signaling (2). Thus, cathepsin B localization may influence PPARα signaling secondary to ligand
delivery by LFABP, in addition to the impact on VLDL and FFA trafficking described in the
present study. This phenomenon could contribute to worsening dyslipidemia. It has also been
observed that PPARα signaling in conjunction with IL-6 mediated inflammation contributes to
increased LFABP expression and post-prandial increases in FFA uptake (29). Disruption of this
process by cathepsin B could lead to systemic increases in FFA as a result of reduced hepatic
FFA uptake by LFABP and CD36, which would most certainly be compensated for by the body
in some way, or manifest in a pathology. Elevated serum FFA would lead to inflammation and
peripheral insulin resistance as a result of the toxic effect of elevated serum FFA. This could
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have a downstream impact of increased pyruvate carboxylase flux and thus lead to the
progression of type II diabetes mellitus by elevating hepatic acetyl-CoA (48).
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